BIONCOTECH is a company dedicated to the development of new drugs in the field of immuno-oncology that is now in the clinical stage. Bioncotech is financed by a Venture Capital company specialised in the sector with offices in Madrid and Valencia. Its mission is the development of new advanced therapies, based on RNA against new and validated therapeutic targets in cancer and immune cells. Its team of scientists, experts in drug development, with the support of different scientific and clinical advisers of world renown, is dedicated to bringing their therapies to patients.
The leading Bioncotech drug, BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal processing of the antigens and their presentation to the adaptive immune system. BO-112 initiates a powerful immune reaction (transforming 'cold' tumors into 'hot' tumors), achieving a highly synergistic therapy with inhibitors of the immune system's control points, and thus achieving deep and sustained anti-tumor responses. Currently, BO-112 is being investigated in clinical trials as a monotherapy, and in combination with inhibitors of immune system checkpoints.
The information contained in this business data sheep has been provided by the company and the University of Valencia Science Park Foundation (FPCUV) is not responsible for its content.
Download Impulse to Business Development Programme (PIDE)'s fileINNOVATIVE ASPECTS
COMPETITIVE ADVANTAGES
BO-112 presents an important competitive advantage over TLR3 activating drugs, and that is in addition to it being able to activate the TLR3 pathways: It is capable of activating the cytosolic helicases MDA5 / RIG1, which induce the death of tumor cells at an early stage, a relevant step for the subsequent efficient immune response.
Linkedin
